Q3 EPS Forecast for Mersana Therapeutics Lifted by Analyst

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Wedbush upped their Q3 2025 earnings per share (EPS) estimates for shares of Mersana Therapeutics in a report issued on Wednesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.17) per share for the quarter, up from their prior estimate of ($4.53). Wedbush currently has a “Outperform” rating and a $75.00 price objective on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q4 2025 earnings at ($1.39) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($1.38) EPS, Q2 2026 earnings at ($1.39) EPS, Q3 2026 earnings at ($1.39) EPS, Q4 2026 earnings at ($0.87) EPS, FY2026 earnings at ($4.81) EPS, FY2027 earnings at ($3.12) EPS and FY2028 earnings at ($2.41) EPS.

Several other equities research analysts have also commented on MRSN. Truist Financial cut their target price on Mersana Therapeutics from $250.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday. Wall Street Zen lowered Mersana Therapeutics to a “strong sell” rating in a research report on Saturday, August 2nd. BTIG Research restated a “buy” rating and set a $17.00 target price on shares of Mersana Therapeutics in a research report on Wednesday. William Blair restated an “outperform” rating on shares of Mersana Therapeutics in a research report on Tuesday, June 3rd. Finally, Guggenheim cut their target price on Mersana Therapeutics from $125.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $56.60.

Mersana Therapeutics Trading Down 3.5%

NASDAQ MRSN opened at $7.16 on Monday. The business’s 50-day moving average price is $8.05 and its two-hundred day moving average price is $9.93. Mersana Therapeutics has a 12 month low of $5.21 and a 12 month high of $70.75. The firm has a market capitalization of $35.73 million, a PE ratio of -0.49 and a beta of 0.83.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($4.08) EPS for the quarter, missing analysts’ consensus estimates of ($3.75) by ($0.33). Mersana Therapeutics had a negative net margin of 212.94% and a negative return on equity of 990.16%. The company had revenue of $3.06 million during the quarter, compared to the consensus estimate of $6.06 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Mersana Therapeutics during the 1st quarter worth approximately $45,000. Novo Holdings A S acquired a new position in Mersana Therapeutics during the 4th quarter worth approximately $6,078,000. Nuveen Asset Management LLC raised its stake in Mersana Therapeutics by 53.6% during the 4th quarter. Nuveen Asset Management LLC now owns 232,223 shares of the company’s stock worth $332,000 after buying an additional 81,022 shares during the period. Pallas Capital Advisors LLC acquired a new position in Mersana Therapeutics during the 1st quarter worth approximately $33,000. Finally, BNP Paribas Financial Markets raised its stake in Mersana Therapeutics by 52.3% during the 4th quarter. BNP Paribas Financial Markets now owns 361,147 shares of the company’s stock worth $516,000 after buying an additional 123,949 shares during the period. 93.92% of the stock is owned by institutional investors and hedge funds.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.